Dare Bioscience, Inc. quarterly report, Q2 FY2017

Dare Bioscience, Inc. (formerly Cerulean Pharma Inc.) — 2017 Q2 Form 10-Q

Reporting period: Quarter and six months ended June 30, 2017. The financial statements report Cerulean’s historical oncology business and do not include the July 2017 acquisition of Private Daré or the sale of Cerulean’s platform to Novartis.

Financial performance and liquidity

MetricThree months ended June 30, 2017Six months ended June 30, 2017Comparable 2016 period
Revenue$0.642 million$1.834 millionNone
Research and development expense$1.292 million$5.943 million$7.522 million / $17.292 million
General and administrative expense$3.375 million$6.962 million$2.773 million / $5.891 million
Operating loss$4.025 million$9.571 million$10.295 million / $23.183 million
Net loss$4.135 million$10.474 million$10.859 million / $24.401 million
Net loss per share$1.42$3.61$3.97 / $8.92
Cash used in operating activitiesNot stated separately$15.416 million$24.501 million

Revenue came from the Novartis research collaboration. No gross profit or margin is reported; the filing does not provide a clear basis for calculating one. The six-month operating results include a $1.5 million gain from the March sale of CRLX101 and CRLX301 to BlueLink.

At June 30, cash and cash equivalents were $7.244 million; current assets were $8.134 million and current liabilities $3.349 million. Total assets were $8.151 million and stockholders’ equity $4.059 million. No loan payable remained at quarter-end: Cerulean paid Hercules $12.4 million in March to settle and terminate the loan. Cash fell by $27.706 million during the first half of 2017.

Material changes and subsequent transactions

  • Compared with the first half of 2016, R&D expense declined 66%, primarily as clinical and manufacturing work wound down and product assets and related trial contracts were transferred to BlueLink. Net loss narrowed by about 57%.
  • G&A expense rose 18% in the first half, reflecting transaction-related legal and accounting costs, restructuring expenses and a lease termination charge.
  • On July 19, 2017, Cerulean acquired Private Daré in a stock transaction. Former Private Daré stockholders received approximately 51% of the combined company; Private Daré is the accounting acquirer under reverse-merger accounting. Purchase accounting and pro forma results were not yet available.
  • On July 19, Cerulean sold its Dynamic Tumor Targeting platform to Novartis for $6.0 million. On July 20, the company changed its name to Daré Bioscience, Inc., effected a 1-for-10 reverse stock split and began trading as DARE. These transactions are not reflected in the June 30 balance sheet.

Outlook, commentary and risks

Daré’s post-transaction focus is women’s reproductive health. Its lead candidate, Ovaprene, is a non-hormonal intravaginal contraceptive ring. Management estimated that resources, including the post-quarter Novartis sale proceeds, would fund planned operations for approximately two years and support a postcoital test (PCT) trial. This estimate depends on assumptions and does not assure sufficient funding for later development; the company expects to seek additional financing for continued development, including a pivotal study.

  • At the time of filing, management planned to begin a PCT trial in approximately 15–30 women in the second half of 2017, with results then anticipated in Q3 2019. Subject to successful results and regulatory clearance, it anticipated a pivotal trial beginning in 2019 and a potential PMA filing during or before Q4 2021. These are forward-looking plans, not achieved milestones.
  • Ovaprene was the company’s sole product candidate. Development and commercialization depend on clinical safety and efficacy, FDA requirements for a drug-device combination, and the continued ADVA-Tec license. The license includes development spending obligations, milestone payments of up to $14.6 million, potential sales-based royalties and up to $20 million in commercial milestones.
  • Key risks include the need for additional capital and possible dilution, clinical or regulatory delays or failure, reliance on ADVA-Tec and other third parties for manufacturing and development, limited staffing, and competition and reimbursement uncertainty. The filing reported three full-time employees after the transaction.
  • The earlier CRLX101 renal cancer study did not show a statistically significant difference in median progression-free survival or objective response rate versus standard of care; Cerulean discontinued development in that indication and later sold CRLX101 and CRLX301.

Investor verification points

  • Confirm the post-transaction cash position and expected cash runway, including the timing and use of the $6.0 million Novartis proceeds and any transaction-related costs.
  • Track Ovaprene PCT trial initiation, enrollment, results and subsequent FDA interactions; compare actual progress with the stated timeline.
  • Review the completed purchase-price allocation, pro forma financials and accounting treatment of the reverse merger when subsequently filed.
  • Assess ADVA-Tec license obligations, manufacturing readiness and the financing required to meet development and annual spending commitments.
  • Distinguish historical Cerulean results from the future operating results of the combined Daré business.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.